Wang Ruihan, Wang Fangqian, Lu Shan, Gao Bin, Kan Yuanqing, Yuan Tong, Xu Yisheng, Yuan Chen, Guo Daqiao, Fu Weiguo, Yu Xiaohua, Si Yi
Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, 200032, PR China.
Institute of Vascular Surgery, Fudan University, Shanghai, 200032, PR China.
Bioact Mater. 2023 Apr 21;27:394-408. doi: 10.1016/j.bioactmat.2023.04.006. eCollection 2023 Sep.
The efficacy of stem cell therapy is substantially compromised due to low cell survival rate and poor local retention post-delivery. These issues drastically limit the application of stem cells for ischemic limb therapy, which requires effective blood perfusion and skeletal muscle regeneration. Herein, based on microfluidic technology, an integrated stem cell and cytokine co-delivery system designed for functional ischemic limb salvage was constructed by first incorporating the myogenic cytokine, fibroblast growth factor 19 (FGF19), into microspheres composed of methacrylate gelatin (GelMA). Then adipose-derived stem cells (ADSCs) were highly absorbed into the porous structure of the microspheres, overcoming the insufficient loading efficiency and activities by conventional encapsulation strategy. The fabricated ADSCs/FGF19@μsphere system demonstrated a uniform size of about 180 μm and a highly porous structure with pore sizes between 20 and 40 μm. The resultant system allowed high doses of ADSCs to be precisely engrafted in the lesion and to survive, and achieved sustained FGF19 release in the ischemic region to facilitate myoblast recruitment and differentiation and myofibrils growth. Furthermore, the combination of ADSCs and FGF19 exhibited a positive synergistic effect which substantially improved the therapeutic benefit of angiogenesis and myogenesis, both and . In summary, a stem cell and cytokine co-delivery system with the properties of easy preparation and minimal invasiveness was designed to ensure highly efficient cell delivery, sustained cytokine release, and ultimately realizes effective treatment of ischemic limb regeneration.
由于细胞存活率低和递送后局部滞留性差,干细胞疗法的疗效大打折扣。这些问题极大地限制了干细胞在缺血肢体治疗中的应用,而缺血肢体治疗需要有效的血液灌注和骨骼肌再生。在此,基于微流控技术,构建了一种用于功能性缺血肢体挽救的集成干细胞和细胞因子共递送系统。首先将成肌细胞因子成纤维细胞生长因子19(FGF19)掺入由甲基丙烯酸明胶(GelMA)组成的微球中。然后脂肪来源的干细胞(ADSCs)被高度吸收到微球的多孔结构中,克服了传统封装策略中装载效率和活性不足的问题。制备的ADSCs/FGF19@μsphere系统显示出均匀的尺寸,约为180μm,具有高度多孔的结构,孔径在20至40μm之间。所得系统允许高剂量的ADSCs精确植入病变部位并存活,并在缺血区域实现FGF19的持续释放,以促进成肌细胞的募集、分化和肌原纤维生长。此外,ADSCs和FGF19的组合表现出积极的协同作用,显著提高了血管生成和肌生成的治疗效果。总之,设计了一种易于制备且微创的干细胞和细胞因子共递送系统,以确保高效的细胞递送、细胞因子的持续释放,并最终实现对缺血肢体再生的有效治疗。